NOT KNOWN FACTS ABOUT COPYRIGHT 1 MG-SEMAGLUTIDE

The demo attained both of those its Main endpoints, with semaglutide 2.4 mg demonstrating statistically important and remarkable improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH as compared to placebo.1The developmental and wel